Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

[...] er limit of normal) Creatinine<1.5 × ULN AST/ALT < 1.5×ULN； Urine test: Urine protein<2+; If urine protein is ≥ 2+, the 24-hour urine protein quantification display must show protein ≤ 1g Thyroid stimulating hormone (TSH) ≤ upper limit of normal (U [...] significant bleeding tendencies within the previous month; Urine routine shows that urine protein is ≥ 2+and confirms that 24-hour urine protein quantification is>1g; Suffering from serious cardiovascular and cerebrovascular diseases, including but not limited to those that meet NYHA criteria (Grade III or higher), or myocardial infarction or cerebr [...] [...]

[...] o meet the inclusion criteria will be randomly divided into fourtwo groups (Group A, and Group B,Group C, Group D) at a ratio of 1:1:1:1, and stratified according to T stage and N stage. The ad [...] )+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles; Group C： albumin-bound paclitaxe (260 mg/m²,d 1, 6 cycles)+Carboplatin (AUC=5,d 1, 6 cycles)+Camrelizumab (200 mg, , d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle; Group D: albumin-bound paclitaxe (125 mg/m²,d 1,8,15,6 cycles)+Carboplatin (AUC=5, d 1, 6 cycles)+Camrelizu [...] Primary endpoint: Pathological complete respon [...] [...]

Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab Asas Neoadjuvant Therapy for Early TNBC